HOME >> MEDICINE >> NEWS
Targeted therapy shows significant benefits over standard treatment for advanced kidney cancer

ATLANTA According to a new study, the drug sunitinib malate (Sutent) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

"This drug has shown more activity as a single agent against advanced kidney cancer than any other drug I've studied in the past 15 years," said the study's lead author Robert J. Motzer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). "I continue to be encouraged by its effectiveness in treating patients with this aggressive disease," said Dr. Motzer, who is a leader in the treatment of kidney cancer and conducted the earliest clinical trials on sunitinib (initially referred to as SU11248).

Interferon-alpha (IFN-) is one of the standard treatments for advanced kidney cancer, however only about 15 percent of patients respond to this immunotherapy. Sunitinib targets receptors on kidney cancer cells that may play a role in tumor growth and the development of blood vessels that feed a tumor. Previous clinical trials, also led by Dr. Motzer, showed that sunitinib caused some renal cell cancers to shrink, but this study is the first to demonstrate its effectiveness as a first-line therapy compared with standard cytokine therapy with IFN-.

The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN- as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-. This outcome was statistical
'"/>

Contact: Maria Connizzo
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
4-Jun-2006


Page: 1 2

Related medicine news :

1. Targeted, oral agent Enzastaurin shows favorable results
2. Targeted initiatives can encourage people to walk more
3. Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
4. Targeted cancer drugs may work by disrupting balance of cellular signals
5. Targeted melanoma education of high risk groups improves screening
6. Targeted lymph node examination improves staging of colon cancer
7. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
8. Chemotherapy with bevacizumab increases risk of blood clots in arteries
9. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
10. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
11. Hormone therapy offers new hope for ovarian cancer patients

Post Your Comments:
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... that he says will reveal biblical truth and expose popular lies regarding proper relationships ... Say Don’t Have Sex”, immediately goes into the core of the subject by explaining ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... The Celebrity ... or cocktail dresses similar to those of celebrities will have the opportunity to get ... at checkout. This ensures that people do not have to use coupon codes or ...
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the Inc. ... in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by ... of obese Americans outnumber merely overweight Americans, Samir Becic emphatically declared a war on ... American society right now," Becic said. "We must understand the magnitude of this discovery. ...
(Date:7/2/2015)... WIsconsin (PRWEB) , ... July 02, 2015 , ... ... for the parking structure retrofit project at the University of Minnesota, they knew ... is that it would also be an award-winning choice: the total energy savings ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ... today that its common shares have been approved for listing ... symbol "EPIX". ESSA will begin trading on NASDAQ ... on the TSX Venture Exchange under the symbol "EPI". ... shares on the NASDAQ, each of the Company,s outstanding special ...
(Date:7/2/2015)... LAUDERDALE, Fla. , July 2, 2015 /PRNewswire/ ... Co., is pleased to announce that its Consumer ... ("Insight Beverages") to Kerry Group plc (ISE: KRZ) ... on taste and nutrition systems, as well as ... beverage and pharmaceutical markets. Farlie Turner served as ...
(Date:7/2/2015)... YORK , July 2, 2015 ... a conspicuously high-growth market segment in hematology testing, ... publisher said that Roche,s recent unveiling of its Bloodhound ... the cobas m 511 hematology analyzer ... only capture growth enjoyed by current leader CellaVision, ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
Cached News: